Page 167 - MI-2-4

Microbes & Immunity A novel anti-EphA8 monoclonal antibody

27. Ren W, Chen S, Liu G, Wang X, Ye H, Xi Y. TUSC7 acts (CD44 and CD133) in patients with squamous cell carcinoma.
as a tumor suppressor in colorectal cancer. Am J Transl Res. Int J Hematol Oncol Stem Cell Res. 2024;18(1):92-99.
2017;9(9):4026-4035.
doi: 10.18502/ijhoscr.v18i1.14748
28. Yan Y, Wang Q, Yan XL, et al. miR-10a controls glioma
migration and invasion through regulating epithelial- 34. Da Silva DD, Araldi RP, Belizario MR, Rocha WG,
mesenchymal transition via EphA8. FEBS Lett. Maciel RMB, Cerutti JM. DLK1 is associated with stemness
2015;589(6):756-765. phenotype in medullary thyroid carcinoma cell lines. Int J
Mol Sci. 2024;25(22):11924.
doi: 10.1016/j.febslet.2015.02.005
doi: 10.3390/ijms252211924
29. Satofuka H, Suzuki H, Tanaka T, Li G, Kaneko MK,
Kato Y. Development of an anti-human EphA2 monoclonal 35. Zhou Y, Sakurai H. Emerging and diverse functions of the
antibody Ea2Mab-7 for multiple applications. Biochem EphA2 noncanonical pathway in cancer progression. Biol
Biophys Rep. 2025;42:101998. Pharm Bull. 2017;40(10):1616-1624.
doi: 10.1016/j.bbrep.2025.101998 doi: 10.1248/bpb.b17-00446
30. Ubukata R, Suzuki H, Hirose M, et al. Establishment of 36. Hosking M, Shirinbak S, Omilusik K, et al. 268 development
a highly sensitive and specific anti-EphB2 monoclonal of FT825/ONO-8250: An off-the-shelf CAR-T cell
antibody (Eb2Mab-12) for flow cytometry. MI. 2025:5728. with preferential HER2 targeting and engineered to
enable multi-antigen targeting, improve trafficking, and
doi: 10.36922/mi.5728
overcome immunosuppression. J Immunother Cancer.
31. Nanamiya R, Suzuki H, Kaneko MK, Kato Y. Development 2023;11(Suppl 1):A307-A307.
of an anti-EphB4 monoclonal antibody for multiple
applications against breast cancers. Monoclon Antib doi: 10.1136/jitc-2023-SITC2023.0268
Immunodiagn Immunother. 2023;42(5):166-177. 37. Chalise L, Kato A, Ohno M, et al. Efficacy of cancer-specific
doi: 10.1089/mab.2023.0015 anti-podoplanin CAR-T cells and oncolytic herpes virus
G47Δ combination therapy against glioblastoma. Mol Ther
32. Suzuki H, Ohishi T, Tanaka T, Kaneko MK, Kato Y. A cancer- Oncolytics. 2022;26:265-274.
specific monoclonal antibody against podocalyxin exerted
antitumor activities in pancreatic cancer xenografts. Int J doi: 10.1016/j.omto.2022.07.006
Mol Sci. 2023;25(1):161. 38. Mishima Y, Okada S, Ishikawa A, et al. Development of
doi: 10.3390/ijms25010161 chimeric antigen receptor T cells targeting cancer-expressing
podocalyxin. Regen Ther. 2025;28:292-300.
33. Paya L, Rafat A, Talebi M, et al. The effect of tumor resection
and radiotherapy on the expression of stem cell markers doi: 10.1016/j.reth.2024.12.010

Volume 2 Issue 4 (2025) 159 doi: 10.36922/MI025060010